Wed, 07th Dec 2022 08:09
PARIS, Dec 7 (Reuters) - Sanofi shares rose by around 8% in early Paris stockmarket trading on Wednesday after the company avoided thousands of U.S. lawsuits claiming that the heartburn drug Zantac caused cancer.
GSK Plc, Pfizer Inc, and unlisted Boehringer Ingelheim were also among the companies benefitting from the court ruling. (Reporting by Tassilo Hummel; Editing by Sudip Kar-Gupta)
FRANKFURT, June 27 (Reuters) - Germany's influential vaccine advisory panel said on Thursday all infants in the country should receive AstraZeneca a...
June 20 (Reuters) - A bid by GSK and other drugmakers to stop more than 70,000 lawsuits in Delaware over discontinued heartburn drug Zantac has rece...
June 10 (Reuters) -
June 10 (Reuters) - A woman who claimed in a lawsuit that GSK's discontinued heartburn drug Zantac caused her breast cancer dropped her case shortly...
CHICAGO, June 7 (Reuters) - The outbreak of bird flu in U.S. dairy cows has now been confirmed in Minnesota and Iowa, bringing to 11 the total numbe...
Sanofi (SAN.PA)
Glaxosmithkline (GSK)
Pfizer (PFE.US)